NAPKON Pediatrics Module
1.0.0 - trial-use

NAPKON Pediatrics Module - Local Development build (v1.0.0). See the Directory of published versions

ValueSet: Immunosuppressive Permanent Medications ATC

Summary

Defining URL:https://www.napkon.de/fhir/ValueSet/immunosuppressive-permament-medications-atc
Version:1.0.0
Name:ImmunosuppressivePermanentMedicationsATC
Title:Immunosuppressive Permanent Medications ATC
Status:Active as of 2021-10-05
Definition:

Immunosuppressive Medications ATC codes

Publisher:Charité - Universitätsmedizin Berlin
Source Resource:XML / JSON / Turtle

References

Logical Definition (CLD)

This value set includes codes based on the following rules:

  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a A14A
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01EG
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L04
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01B
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01A
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01XC
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01EJ
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L01E
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a R03DX
  • ​Include codes from http://fhir.de/CodeSystem/bfarm/atc where concept is-a L03AB

 

Expansion

This value set contains 324 concepts

Expansion based on http://fhir.de/CodeSystem/bfarm/atc v2021 (CodeSystem)

​All codes in this table are from the system http://fhir.de/CodeSystem/bfarm/atc

CodeDisplayDefinition
​ A14AANABOLE STEROIDE
​ A14AAAndrostan-Derivate
​ A14AA01Androstanolon
​ A14AA02Stanozolol
​ A14AA03Metandienon
​ A14AA04Metenolon
​ A14AA05Oxymetholon
​ A14AA06Quinbolon
​ A14AA07Prasteron
​ A14AA08Oxandrolon
​ A14AA09Norethandrolon
​ A14AA10Chlordehydromethyltestosteron
​ A14AA11Clostebol
​ A14AA50Andere Androstan-Derivate, Kombinationen
​ A14ABEstren-Derivate
​ A14AB01Nandrolon
​ A14AB02Ethylestrenol
​ A14AB03Oxaboloncipionat
​ L01EGMammalian target of rapamycin (mTOR)-Kinase-Inhibitoren
​ L01EG01Temsirolimus
​ L01EG02Everolimus
​ L01EG03Ridaforolimus
​ L04IMMUNSUPPRESSIVA
​ L04AIMMUNSUPPRESSIVA
​ L04AASelektive Immunsuppressiva
​ L04AA02Muromonab-CD3
​ L04AA03Antilymphozytäres Immunglobulin (Pferd)
​ L04AA04Antithymozytäres Immunglobulin (Kaninchen)
​ L04AA06Mycophenolsäure
​ L04AA10Sirolimus
​ L04AA13Leflunomid
​ L04AA15Alefacept
​ L04AA18Everolimus
​ L04AA19Gusperimus
​ L04AA21Efalizumab
​ L04AA22Abetimus
​ L04AA23Natalizumab
​ L04AA24Abatacept
​ L04AA25Eculizumab
​ L04AA26Belimumab
​ L04AA27Fingolimod
​ L04AA28Belatacept
​ L04AA29Tofacitinib
​ L04AA31Teriflunomid
​ L04AA32Apremilast
​ L04AA33Vedolizumab
​ L04AA34Alemtuzumab
​ L04AA35Begelomab
​ L04AA36Ocrelizumab
​ L04AA37Baricitinib
​ L04AA38Ozanimod
​ L04AA39Emapalumab
​ L04AA40Cladribin
​ L04AA41Imlifidase
​ L04AA42Siponimod
​ L04AA43Ravulizumab
​ L04AA44Upadacitinib
​ L04AA45Filgotinib
​ L04AA46Itacitinib
​ L04AA47Inebilizumab
​ L04AA48Belumosudil
​ L04AA49Peficitinib
​ L04AA50Ponesimod
​ L04AA51Anifrolumab
​ L04AA52Ofatumumab
​ L04AA53Teprotumumab
​ L04ABTumornekrosefaktor alpha (TNF-alpha)-Inhibitoren
​ L04AB01Etanercept
​ L04AB02Infliximab
​ L04AB03Afelimomab
​ L04AB04Adalimumab
​ L04AB05Certolizumab pegol
​ L04AB06Golimumab
​ L04AB07Opinercept
​ L04ACInterleukin-Inhibitoren
​ L04AC01Daclizumab
​ L04AC02Basiliximab
​ L04AC03Anakinra
​ L04AC04Rilonacept
​ L04AC05Ustekinumab
​ L04AC07Tocilizumab
​ L04AC08Canakinumab
​ L04AC09Briakinumab
​ L04AC10Secukinumab
​ L04AC11Siltuximab
​ L04AC12Brodalumab
​ L04AC13Ixekizumab
​ L04AC14Sarilumab
​ L04AC15Sirukumab
​ L04AC16Guselkumab
​ L04AC17Tildrakizumab
​ L04AC18Risankizumab
​ L04AC19Satralizumab
​ L04AC20Netakimab
​ L04AC21Bimekizumab
​ L04ADCalcineurin-Inhibitoren
​ L04AD01Ciclosporin
​ L04AD02Tacrolimus
​ L04AD03Voclosporin
​ L04AXAndere Immunsuppressiva
​ L04AX01Azathioprin
​ L04AX02Thalidomid
​ L04AX03Methotrexat
​ L04AX04Lenalidomid
​ L04AX05Pirfenidon
​ L04AX06Pomalidomid
​ L04AX07Dimethylfumarat
​ L04AX08Darvadstrocel
​ L04AX09Diroximelfumarat
​ L04AX18Humane allogene mesenchymale Stromazellen
​ L01BANTIMETABOLITEN
​ L01BAFolsäure-Analoga
​ L01BA01Methotrexat
​ L01BA03Raltitrexed
​ L01BA04Pemetrexed
​ L01BA05Pralatrexat
​ L01BBPurin-Analoga
​ L01BB02Mercaptopurin
​ L01BB03Tioguanin
​ L01BB04Cladribin
​ L01BB05Fludarabin
​ L01BB06Clofarabin
​ L01BB07Nelarabin
​ L01BCPyrimidin-Analoga
​ L01BC01Cytarabin
​ L01BC02Fluorouracil
​ L01BC03Tegafur
​ L01BC04Carmofur
​ L01BC05Gemcitabin
​ L01BC06Capecitabin
​ L01BC07Azacitidin
​ L01BC08Decitabin
​ L01BC09Floxuridin
​ L01BC52Fluorouracil, Kombinationen
​ L01BC53Tegafur, Kombinationen
​ L01BC59Trifluridin, Kombinationen
​ L01BC63Tegafur und Uracil
​ L01BC73Tegafur, Gimeracil und Oteracil
​ L01AALKYLIERENDE MITTEL
​ L01AAStickstofflost-Analoga
​ L01AA01Cyclophosphamid
​ L01AA02Chlorambucil
​ L01AA03Melphalan
​ L01AA05Chlormethin
​ L01AA06Ifosfamid
​ L01AA07Trofosfamid
​ L01AA08Prednimustin
​ L01AA09Bendamustin
​ L01ABAlkylsulfonate
​ L01AB01Busulfan
​ L01AB02Treosulfan
​ L01AB03Mannosulfan
​ L01ACEthylenimine
​ L01AC01Thiotepa
​ L01AC02Triaziquon
​ L01AC03Carboquon
​ L01ADNitrosoharnstoffe
​ L01AD01Carmustin
​ L01AD02Lomustin
​ L01AD03Semustin
​ L01AD04Streptozocin
​ L01AD05Fotemustin
​ L01AD06Nimustin
​ L01AD07Ranimustin
​ L01AD08Uramustin
​ L01AGEpoxide
​ L01AG01Etoglucid
​ L01AXAndere alkylierende Mittel
​ L01AX01Mitobronitol
​ L01AX02Pipobroman
​ L01AX03Temozolomid
​ L01AX04Dacarbazin
​ L01XCMonoklonale Antikörper
​ L01XC01Edrecolomab
​ L01XC02Rituximab
​ L01XC03Trastuzumab
​ L01XC04Alemtuzumab
​ L01XC05Gemtuzumab ozogamicin
​ L01XC06Cetuximab
​ L01XC07Bevacizumab
​ L01XC08Panitumumab
​ L01XC09Catumaxomab
​ L01XC10Ofatumumab
​ L01XC11Ipilimumab
​ L01XC12Brentuximab vedotin
​ L01XC13Pertuzumab
​ L01XC14Trastuzumab emtansin
​ L01XC15Obinutuzumab
​ L01XC16Dinutuximab beta
​ L01XC17Nivolumab
​ L01XC18Pembrolizumab
​ L01XC19Blinatumomab
​ L01XC21Ramucirumab
​ L01XC22Necitumumab
​ L01XC23Elotuzumab
​ L01XC24Daratumumab
​ L01XC25Mogamulizumab
​ L01XC26Inotuzumab ozogamicin
​ L01XC27Olaratumab
​ L01XC28Durvalumab
​ L01XC29Bermekimab
​ L01XC31Avelumab
​ L01XC32Atezolizumab
​ L01XC33Cemiplimab
​ L01XC34Moxetumomab pasudotox
​ L01XC35Tafasitamab
​ L01XC36Enfortumab vedotin
​ L01XC37Polatuzumab vedotin
​ L01XC38Isatuximab
​ L01XC39Belantamab mafodotin
​ L01XC40Dostarlimab
​ L01XC41Trastuzumab deruxtecan
​ L01XC42Prolgolimab
​ L01EJJanus-assoziierte Kinase (JAK)-Inhibitoren
​ L01EJ01Ruxolitinib
​ L01EJ02Fedratinib
​ L01EPROTEINKINASE-INHIBITOREN
​ L01EABCR-ABL-Tyrosinkinase-Inhibitoren
​ L01EA01Imatinib
​ L01EA02Dasatinib
​ L01EA03Nilotinib
​ L01EA04Bosutinib
​ L01EA05Ponatinib
​ L01EA06Asciminib
​ L01EBEpidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren
​ L01EB01Gefitinib
​ L01EB02Erlotinib
​ L01EB03Afatinib
​ L01EB04Osimertinib
​ L01EB05Rociletinib
​ L01EB06Olmutinib
​ L01EB07Dacomitinib
​ L01EB08Icotinib
​ L01ECBRAF-Serin-Threoninkinase-Inhibitoren
​ L01EC01Vemurafenib
​ L01EC02Dabrafenib
​ L01EC03Encorafenib
​ L01EDAnaplastische Lymphomkinase (ALK)-Inhibitoren
​ L01ED01Crizotinib
​ L01ED02Ceritinib
​ L01ED03Alectinib
​ L01ED04Brigatinib
​ L01ED05Lorlatinib
​ L01EEMitogen-aktivierte Proteinkinase (MEK)-Inhibitoren
​ L01EE01Trametinib
​ L01EE02Cobimetinib
​ L01EE03Binimetinib
​ L01EE04Selumetinib
​ L01EFCyclin-abhängige Kinasen (CDK)-Inhibitoren
​ L01EF01Palbociclib
​ L01EF02Ribociclib
​ L01EF03Abemaciclib
​ L01EHHumaner epidermaler Wachstumsfaktor-Rezeptor 2 (HER2)-Tyrosinkinase-Inhibitoren
​ L01EH01Lapatinib
​ L01EH02Neratinib
​ L01EH03Tucatinib
​ L01EKVaskulärer endothelialer Wachstumsfaktor-Rezeptor (VEGFR)-Tyrosinkinase-Inhibitoren
​ L01EK01Axitinib
​ L01EK02Cediranib
​ L01EK03Tivozanib
​ L01ELBruton-Tyrosinkinase (BTK)-Inhibitoren
​ L01EL01Ibrutinib
​ L01EL02Acalabrutinib
​ L01EL03Zanubrutinib
​ L01EMPhosphatidylinositol-3-kinase (Pi3K)-Inhibitoren
​ L01EM01Idelalisib
​ L01EM02Copanlisib
​ L01EM03Alpelisib
​ L01EM04Duvelisib
​ L01EXAndere Proteinkinase-Inhibitoren
​ L01EX01Sunitinib
​ L01EX02Sorafenib
​ L01EX03Pazopanib
​ L01EX04Vandetanib
​ L01EX05Regorafenib
​ L01EX06Masitinib
​ L01EX07Cabozantinib
​ L01EX08Lenvatinib
​ L01EX09Nintedanib
​ L01EX10Midostaurin
​ L01EX11Quizartinib
​ L01EX12Larotrectinib
​ L01EX13Gilteritinib
​ L01EX14Entrectinib
​ L01EX15Pexidartinib
​ L01EX16Erdafitinib
​ L01EX17Capmatinib
​ L01EX18Avapritinib
​ L01EX19Ripretinib
​ L01EX20Pemigatinib
​ L01EX21Tepotinib
​ L01EX22Selpercatinib
​ L01EX23Pralsetinib
​ R03DXAndere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung
​ R03DX01Amlexanox
​ R03DX02Eprozinol
​ R03DX03Fenspirid
​ R03DX05Omalizumab
​ R03DX06Seratrodast
​ R03DX07Roflumilast
​ R03DX08Reslizumab
​ R03DX09Mepolizumab
​ R03DX10Benralizumab
​ R03DX11Tezepelumab
​ R03DX50Andere systemische Antiasthmatika, Kombinationen
​ L03ABInterferone
​ L03AB01Interferon alfa, natürlich
​ L03AB02Interferon beta, natürlich
​ L03AB03Interferon gamma
​ L03AB04Interferon alfa-2a
​ L03AB05Interferon alfa-2b
​ L03AB06Interferon alfa-n1
​ L03AB07Interferon beta-1a
​ L03AB08Interferon beta-1b
​ L03AB09Interferon alfacon-1
​ L03AB10Peginterferon alfa-2b
​ L03AB11Peginterferon alfa-2a
​ L03AB12Albinterferon alfa-2b
​ L03AB13Peginterferon beta-1a
​ L03AB14Cepeginterferon alfa-2b
​ L03AB15Ropeginterferon alfa-2b
​ L03AB18Interferon gamma-1b
​ L03AB60Peginterferon alfa-2b, Kombinationen
​ L03AB61Peginterferon alfa-2a, Kombinationen

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
Source The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code